5 completed, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow JNJ-39393406: new trials by email Literature Review of JNJ-39393406 trials Research Report on JNJ-39393406
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive JNJ-39393406, Placebo - Depression | Phase 2 | Completed | Tangent Data | 80 | 2016-02-01 | 2020-05-22 |
| Test of Novel Drug for Smoking Cessation Active JNJ Drug, Placebo pill - Smoking Cessation | Phase 2 | Completed | Chengappa, K.N. Roy, MD | 36 | 2014-11-01 | 2018-08-15 |
| Novel Smoking Cessation Drug for Schizophrenia Active JNJ Drug, Placebo Pill - Smoking Cessation | Phase 2 | Completed | K.N. Roy Chengappa | 62 | 2014-09-01 | 2019-04-02 |
| A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers JNJ-39393406, Placebo - Healthy Volunteers | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 12 | 2010-09-01 | 2013-07-24 |
| The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients JNJ-39393406, placebo - Schizophrenia, Alzheimer's Disease | Phase 1 | Terminated | Janssen Pharmaceutica N.V., Belgium | 47 | 2009-08-01 | 2012-11-08 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants JNJ-39393406, Placebo - Healthy | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 88 | 2009-01-01 | 2014-01-24 |
Schizophrenia (2) · Smoking Cessation (2) · Alzheimer Disease (1) · Cognition Disorders (1) · Depression (1) · Psychotic Disorders (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Chengappa, K.N. Roy, MD (1) · Janssen Pharmaceutica N.V., Belgium (1) · K.N. Roy Chengappa (1) · Tangent Data (1)
United States (2) · Belgium (1) · Germany (1) · Moldova (1) · Romania (1)
K.N. Roy Chengappa, MD (1) · Kenneth Perkins, PhD (1) · Michael Davidson, M.D. (1)
UH3TR000958 (2)